Brief: Madrigal Pharmaceuticals Q4 EPS USD -2.57
19/02/2026 12:00
Feb 19 (Reuters) - Madrigal Pharmaceuticals Q4 product revenue USD 321.083 million. Q4 operating expenses USD 380.692 million Q4 net income USD -58.575 million Q4 operating income USD -59.609 million
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)